{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:14:42Z","timestamp":1793499282573,"version":"4.5.0"},"reference-count":47,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Somatostatin receptor ligands (SRLs) are the cornerstone medical treatments for acromegaly; however, many patients remain unresponsive to SRLs. Well-established predictive markers of response are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to explore the relationship between responsiveness to SRLs relative to somatostatin (SST)2A and 5 receptor expression, adenoma granularity, and T2-weighted magnetic resonance imaging (MRI) signal intensity (T2WSI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentric, prospective, observational cohort study, in France. Forty-nine na\u00efve patients (ie, patients without preoperative SRL treatment) with active acromegaly following surgery were treated with octreotide (group 1; n = 47), or pasireotide if uncontrolled under first-generation SRLs (group 2; n = 9). Data were collected at baseline and months 3 and 6. Biochemical measurements, immunohistochemistry studies, and MRI readings were centralized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In group 1, IGF-I decrease from baseline to month 6 positively correlated with SST2A immunoreactive score (IRS), P = 0.01. Densely granulated\/intermediate adenomas had a greater IGF-I and GH decrease under octreotide compared with sparsely granulated adenomas (P = 0.02 and P = 0.006, respectively), and expressed greater levels of SST2A (P &amp;lt; 0.001), coupled with lower levels of SST5 (P = 0.004). T2WSI changed between preoperative MRI and month 6 MRI in one-half of the patients. Finally, SST5 IRS was higher in preoperative hyperintense compared with preoperative hypointense adenomas (P = 0.04), and most sparsely granulated and most hyperintense adenomas expressed high SST5 levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We prospectively confirm that SST2A and adenoma granularity are good predictors of response to octreotide. We propose the IRS for scoring system harmonization. MRI sequences must be optimized to be able to use the T2WSI as a predictor of treatment response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac512","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:58:32Z","timestamp":1663865912000},"page":"2982-2991","source":"Crossref","is-referenced-by-count":49,"title":["Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly\u2014A Prospective Study"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-7258","authenticated-orcid":false,"given":"Mirela-Diana","family":"Ilie","sequence":"first","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon , Lyon 69001 , France"},{"name":"Endocrinology Department, \u201cC.I. Parhon\u201d National Institute of Endocrinology , Bucharest 011863 , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-3306","authenticated-orcid":false,"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Bordeaux University Hospital , Pessac 33600 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon , Lyon 69001 , France"},{"name":"Pathology Department, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron 69500 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-4793","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Bonneville","sequence":"additional","affiliation":[{"name":"Departments of Medical Imaging and Endocrinology, Li\u00e8ge University Hospital , Li\u00e8ge 4000 , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Moreau-Grang\u00e9","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Disorders, Rouen University Hospital , Rouen 76000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-5845","authenticated-orcid":false,"given":"Franck","family":"Schillo","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Besan\u00e7on University Hospital , Besan\u00e7on 25030 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4320-2601","authenticated-orcid":false,"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Reims University Hospital , Reims 51092 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-6173","authenticated-orcid":false,"given":"Anne","family":"Barlier","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Conception University Hospital, AP-HM , Marseille 13005 , France"},{"name":"Aix-Marseille University, Inserm, MMG , Marseille 13011 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-887X","authenticated-orcid":false,"given":"Dominique","family":"Figarella-Branger","sequence":"additional","affiliation":[{"name":"Pathology and Neuropathology Department, Timone University Hospital, AP-HM , Marseille 13005 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-9758","authenticated-orcid":false,"given":"S\u00e9gol\u00e8ne","family":"Bisot-Locard","sequence":"additional","affiliation":[{"name":"Medical Oncology, Novartis , Rueil Malmaison 92563 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-3231","authenticated-orcid":false,"given":"Alexandre","family":"Santos","sequence":"additional","affiliation":[{"name":"Medical Oncology, Novartis , Rueil Malmaison 92563 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Reproduction Disorders, Bic\u00eatre Hospital, AP-HP , Le Kremlin-Bic\u00eatre 94270 , France"},{"name":"Paris-Saclay University, Inserm, \u201cPhysiologie et Physiopathologie Endocriniennes\u201d , Le Kremlin-Bic\u00eatre 91190 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon , Lyon 69001 , France"},{"name":"Endocrinology Department, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron 69500 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"1","key":"2022112301501555600_dgac512-B1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"24","key":"2022112301501555600_dgac512-B2","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2022112301501555600_dgac512-B3","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2022112301501555600_dgac512-B4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2022112301501555600_dgac512-B5","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jc.2014-2900","article-title":"Surgical interventions and medical treatments in treatment-na\u00efve patients with acromegaly: systematic review and meta-analysis","volume":"99","author":"Dabrh AM","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2022112301501555600_dgac512-B6","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications","volume":"159","author":"Chen","year":"2017","journal-title":"Acta Neurochir"},{"issue":"1\u20132","key":"2022112301501555600_dgac512-B7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2010.04.020","article-title":"Pituitary tumours: the SST\/D2 receptors as molecular targets","volume":"326","author":"Hofland","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2022112301501555600_dgac512-B8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2022112301501555600_dgac512-B9","doi-asserted-by":"crossref","first-page":"D17","DOI":"10.1530\/EJE-19-0998","article-title":"Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly","volume":"182","author":"van der Lely","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2022112301501555600_dgac512-B10","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1530\/eje.1.02350","article-title":"Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas","volume":"156","author":"van der Hoek","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2022112301501555600_dgac512-B11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2022112301501555600_dgac512-B12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2022112301501555600_dgac512-B13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2022112301501555600_dgac512-B14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"2022112301501555600_dgac512-B15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1\u20135 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"2022112301501555600_dgac512-B16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2022112301501555600_dgac512-B17","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022112301501555600_dgac512-B18","doi-asserted-by":"crossref","first-page":"677919","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2022112301501555600_dgac512-B19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Pl\u00f6ckinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2022112301501555600_dgac512-B20","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022112301501555600_dgac512-B21","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2022112301501555600_dgac512-B22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2022112301501555600_dgac512-B23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2022112301501555600_dgac512-B24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2022112301501555600_dgac512-B25","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2022112301501555600_dgac512-B26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41598-018-37692-3","article-title":"Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles","volume":"9","author":"Coelho","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"2022112301501555600_dgac512-B27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2022112301501555600_dgac512-B28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1530\/EC-21-0175","article-title":"Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays","volume":"10","author":"Sabbah","year":"2021","journal-title":"Endocr Connect"},{"issue":"4","key":"2022112301501555600_dgac512-B29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"issue":"2","key":"2022112301501555600_dgac512-B30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/ERC-14-0305","article-title":"Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences","volume":"22","author":"Potorac","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2022112301501555600_dgac512-B31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/cancers12041012","article-title":"Gonadotroph tumors show subtype differences that might have implications for therapy","volume":"12","author":"Ilie","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2022112301501555600_dgac512-B32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2022112301501555600_dgac512-B33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"issue":"1","key":"2022112301501555600_dgac512-B34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","article-title":"Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies","volume":"45","author":"Chinezu","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"2022112301501555600_dgac512-B35","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"2022112301501555600_dgac512-B36","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2022112301501555600_dgac512-B37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2022112301501555600_dgac512-B38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2022112301501555600_dgac512-B39","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1210\/jc.2017-00792","article-title":"Estrogen receptor \u03b1, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA","volume":"102","author":"\u00d8ystese","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022112301501555600_dgac512-B40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly: granulation in somatotroph adenomas","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2022112301501555600_dgac512-B41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/EJE-13-0134","article-title":"Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas","volume":"169","author":"Mayr","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2022112301501555600_dgac512-B42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly: intensity of somatotroph adenoma on T2-weighted MRI","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2022112301501555600_dgac512-B43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-18-0254","article-title":"MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis","volume":"180","author":"Bonneville","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2022112301501555600_dgac512-B44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2022112301501555600_dgac512-B45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2022112301501555600_dgac512-B46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"2022112301501555600_dgac512-B47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone\u2013producing and non\u2013growth hormone\u2013producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac512\/46342491\/dgac512.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/2982\/47201326\/dgac512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/2982\/47201326\/dgac512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:52:22Z","timestamp":1669168342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/11\/2982\/6711554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,22]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac512","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,9,22]]}}}